PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor
AffiliationUniv Arizona, Coll Pharm, Dept Pharm Practice & Sci
Univ Arizona, Ctr Canc
Univ Arizona, Coll Med, Dept Med
Univ Arizona, Coll Med, Dept Med Imaging
MetadataShow full item record
PublisherAMER ASSOC CANCER RESEARCH
CitationDavis, L. E., Nicholls, L. A., Babiker, H. M., Liau, J., & Mahadevan, D. (2019). PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor. Cancer immunology research, 7(9), 1396-1400.
JournalCANCER IMMUNOLOGY RESEARCH
RightsCopyright © 2019 American Association for Cancer Research.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractHigh-grade malignant peripheral nerve sheath tumors (MPNST) have a poor prognosis with limited responsiveness to systemic therapy. We document a case of a complete metabolic response to pembrolizumab monotherapy in metastatic disease. Tumor molecular profiling identified programmed-death ligand-1 (PD-L1) positivity. This characteristic provided a rationale for immune-checkpoint therapy. Treatment with pembrolizumab resulted in a complete metabolic response after four cycles of therapy. Patients with PD-L1-positive, metastatic MPNST may be candidates for immune-checkpoint therapy, which may produce a durable completere mission. Future study of anti-PD-1/PD-L1 therapy is warranted.
Note12 month embargo; published online: 1 September 2019
VersionFinal accepted manuscript
SponsorsCCSG P30 supplement from the NCI
- Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.
- Authors: Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner ES, Schwartz PE, Santin AD
- Issue date: 2018 Jul 15
- Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
- Authors: Merhi M, Raza A, Inchakalody VP, Nashwan AJJ, Allahverdi N, Krishnankutty R, Uddin S, Zar Gul AR, Al Homsi MU, Dermime S
- Issue date: 2018
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
- Authors: Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C
- Issue date: 2018 Sep
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
- Authors: Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK
- Issue date: 2018 Apr
- Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
- Authors: Fischer S, Hasan Ali O, Jochum W, Kluckert T, Flatz L, Siano M
- Issue date: 2018